PIQLF (Proteomics International Laboratories) NonCurrent Deferred Revenue: $0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PIQLF Proteomics International Laboratories Ltd PIQLF
31 GF Score
Price $0.26
GF Value $0.64
! 3 Warning Signs
View Full Analysis

What is Proteomics International Laboratories NonCurrent Deferred Revenue?

Proteomics International Laboratories PIQLF -16.13% 31 NonCurrent Deferred Revenue is $0.00 Mil as of Dec. 2025. GuruFocus rates PIQLF with a GF Score™ of 31/100 and a GF Value™ of $0.64. The stock has 3 warning signs investors should review.

Non-Current Deferred Revenue represents the non-current portion of deferred revenue amount as of the balance sheet date. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months.

Proteomics International Laboratories's non-current deferred revenue for the quarter that ended in Dec. 2025 was $0.00 Mil.

Proteomics International Laboratories NonCurrent Deferred Revenue Related Terms

Proteomics International Laboratories NonCurrent Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Proteomics International Laboratories's NonCurrent Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Proteomics International Laboratories NonCurrent Deferred Revenue Chart

Proteomics International Laboratories Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
NonCurrent Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 0.09 0.39 0.25 0.14

Proteomics International Laboratories Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
NonCurrent Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.25 0.00 0.14 0.00
PIQLF
31GF Score
Proteomics International Laboratories Ltd PIQLF
NonCurrent Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Revenue of $0.00 Mil mean?
Proteomics International Laboratories (PIQLF) has a NonCurrent Deferred Revenue of $0.00 Mil as of Dec. 2025. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Proteomics International Laboratories and its competitors.
Is Proteomics International Laboratories' NonCurrent Deferred Revenue too high?
Proteomics International Laboratories' current NonCurrent Deferred Revenue is $0.00 Mil. Overall, Proteomics International Laboratories has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Proteomics International Laboratories' NonCurrent Deferred Revenue compare to VRTX and REGN?
Proteomics International Laboratories' NonCurrent Deferred Revenue of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Revenue for a Biotechnology company?
A good NonCurrent Deferred Revenue depends on the Biotechnology industry context. However, NonCurrent Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Revenue mean?
A high NonCurrent Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Proteomics International Laboratories and its competitors. Proteomics International Laboratories's current NonCurrent Deferred Revenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Proteomics International Laboratories stock overvalued right now?
Proteomics International Laboratories (PIQLF) has a current NonCurrent Deferred Revenue of $0.00 Mil. The stock's GF Value™ is $0.64, compared to a current price of $0.26 — trading 59.4% below its estimated fair value. The current NonCurrent Deferred Revenue is $0.00 Mil. Proteomics International Laboratories' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Revenue calculated?
NonCurrent Deferred Revenue is calculated from a company's financial statements. For Proteomics International Laboratories (PIQLF), the current NonCurrent Deferred Revenue is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Proteomics International Laboratories (PIQLF) Overvalued in 2026?

Based on GuruFocus' analysis, Proteomics International Laboratories stock appears to be undervalued. The current stock price of $0.26 is trading 59.4% below its estimated GF Value™ of $0.64.

Key valuation signals for PIQLF:

  • NonCurrent Deferred Revenue: $0.00 Mil
  • GF Value™: $0.64 vs. price of $0.26 (59.4% below fair value)
  • GF Score™: 31/100 with 3 warning signs

No single metric tells the full story. See the PIQLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Proteomics International Laboratories Business Description

Other Exchanges PIQ:Australia
Address 6 Verdun Street, QEII Medical Centre, QQ Block, Nedlands, Perth, WA, AUS, 6009
Proteomics International Laboratories Ltd is a biological research and drug discovery company. It is a pioneering medical technology company operating at the forefront of predictive diagnostics and precision medicine. The Company specialises in proteomics-the industrial-scale study of the structure and function of proteins. Its pipeline includes Promarker, Pipeline PromarkerD, PromarkerEndo, PromarkerEso, and OxiDx.
31GF Score

Get the complete analysis for PIQLF

NonCurrent Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.26
Price
$0.64
GF Value